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Abstract
Background: Hepatocyte Growth Factor (HGF) is a pleiotropic cytokine of mesenchymal origin that mediates a characteristic
array of biological activities including cell proliferation, survival, motility and morphogenesis. Its high affinity receptor, the
tyrosine kinase Met, is expressed by a wide range of tissues and can be activated by either paracrine or autocrine
stimulation. Adult myogenic precursor cells, the so called satellite cells, express both HGF and Met. Following muscle injury,
autocrine HGF-Met stimulation plays a key role in promoting activation and early division of satellite cells, but is shut off in a
second phase to allow myogenic differentiation. In culture, HGF stimulation promotes proliferation of muscle precursors
thereby inhibiting their differentiation.
Methodology/Principal Findings: Magic-Factor 1 (Met-Activating Genetically Improved Chimeric Factor-1 or Magic-F1) is an
HGF-derived, engineered protein that contains two Met-binding domains repeated in tandem. It has a reduced affinity for
Met and, in contrast to HGF it elicits activation of the AKT but not the ERK signaling pathway. As a result, Magic-F1 is not
mitogenic but conserves the ability to promote cell survival. Here we show that Magic-F1 protects myogenic precursors
against apoptosis, thus increasing their fusion ability and enhancing muscular differentiation. Electrotransfer of Magic-F1
gene into adult mice promoted muscular hypertrophy and decreased myocyte apoptosis. Magic-F1 transgenic mice
displayed constitutive muscular hypertrophy, improved running performance and accelerated muscle regeneration
following injury. Crossing of Magic-F1 transgenic mice with a-sarcoglycan knock-out mice –a mouse model of muscular
dystrophy– or adenovirus-mediated Magic-F1 gene delivery resulted in amelioration of the dystrophic phenotype as
measured by both anatomical/histological analysis and functional tests.
Conclusions/Significance: Because of these features Magic-F1 represents a novel molecular tool to counteract muscle
wasting in major muscular diseases such as cachexia or muscular dystrophy.
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Introduction
Hepatocyte Growth Factor (HGF), also known as Scatter Factor
(SF), is a pleiotropic cytokine of mesenchymal origin that mediates a
characteristicarrayof biologicalactivitiesincludingcellproliferation,
survival, motility and morphogenesis [1–3]. Its high affinity receptor,
the tyrosine kinase Met, is expressed by a wide range of tissues
including epithelial, endothelial, hematopoietic, neuronal and
muscular cells [4,5]. Embryonic muscle precursor cells express
Met and migrate following HGF gradients during embryo
development [6–10]. Genetic impairment of HGF-Met signaling
in mice leads to abnormal muscle development in the limbs, thorax
and tongue [11–13], and newborns -which are ataxic and have
breathing problems- die a few hours later because they cannot suck
mother’s milk [14]. In the adult, the HGF-Met pathway is involved
in muscle regeneration following injury. Muscle satellite cells, which
reside in the stroma of muscular tissues and express both HGF and
Met [15], represent a pool of muscle precursors that are activated
and stimulated to divide when muscle regeneration or adaptive
growth is needed [16,17]. Autocrine HGF-Met stimulation plays a
key role in mediating activation and early division of satellite cells,
but is shut off in a second phase in order to allow the cells to exit the
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3223cell cycle and to enter the differentiation process [18,19]. HGF
stimulation of cultured satellite cells promotes cell proliferation and
inhibits myogenic differentiation [20].
Magic Factor-1 (Met-Activating Genetically Improved Chime-
ric Factor-1 or Magic-F1) is an HGF-derived, engineered protein
that contains two Met-binding domains repeated in tandem. It has
a reduced affinity for Met and, in contrast to HGF, it elicits
activation of the AKT but not the ERK signaling pathway. As a
result of its partial ability to activate Met signaling, Magic-F1 is not
mitogenic but conserves the ability to protect cells against
apoptosis. We have analyzed the effects of Magic-F1 on muscular
cells both in vitro and in mice. We show that Magic-F1 protects
myogenic precursors against apoptosis and thus enhances the
differentiation process, which is naturally accompanied by cell
death. This pro-differentiative effect is observed both in cultured
myogenic cell systems and in two different in vivo models.
Remarkably, constitutive or transient expression of Magic-F1 in
a mouse model of muscular dystrophy partially rescues the
dystrophic phenotype and allows animals to perform better in a
classic tread mill functional test. These features make Magic-F1 a
novel, potential molecular tool to counteract muscle wasting in
major muscular diseases including cachexia and muscular
dystrophy.
Results
Engineering of Magic-F1, a bivalent Met ligand
Mature HGF is a dimeric molecule consisting of a a- and a b-
chain joint by a disulphide bridge [21]. The a-chain contains a
leader peptide for secretion, an N-domain similar to the activation
domain of plasminogen, and four kringle domains (K 1–4) typical
of the blood clotting cascade proteases [22]. In functional terms,
HGF is a bivalent molecule containing two distinct Met binding
sites, one in the a-chain high affinity; [23] and one at in the b-
chain low affinity; [24]. Isolated HGF domains containing only
one receptor binding site (HGF NK1, HGF NK2, HGF a-chain,
HGF b-chain) can bind to the Met receptor but do not activate it
[22–25], thus suggesting that a bivalent molecule is necessary to
achieve receptor activation. Consistent with this idea, some
monovalent scatter factor subdomains (HGF NK1, HGF NK2)
display a partial agonistic activity when they are stabilized in a
dimeric form by extracellular matrix proteoglycans [26]. To
generate new recombinant proteins capable of inducing specific
patterns of biological responses, we engineered several artificial
molecules containing different HGF domain in various combina-
tion. Magic-F1, the prototype of this series, contains the signal
peptide plus the N-domain and the first two kringles repeated in
tandem and joint by a linker (Fig. 1A). A poly-histidine tag was
engineered at the C-terminal end to facilitate protein purification.
Since the high affinity Met binding site lies within the N and K1
domains [23], Magic-F1 is a bivalent ligand. Magic-F1 recombi-
nant protein was produced using both transiently and stably
transfected CHO cells, and was purified by affinity chromatog-
raphy as described in the Experimental Protocol section (Fig. 1B).
The affinity of Magic-F1 for Met was measured in a ELISA
binding assay using a recombinant chimera between Met and the
Fc portion of a human immunoglobulin Fc-Met; [27]. Fc-Met was
absorbed in solid phase and exposed to increasing concentrations
of Magic-F1 or HGF in liquid phase. Binding was revealed using
biotinylated anti-HGF antibodies. This analysis revealed that
Magic-F1 has an affinity for Met that is approximately 7–8 times
lower than that of HGF (i.e. 0.8 nM; Fig. 1C). These data are
consistent with previous measurements that determined the
affinity of different subdomains of HGF for Met [23].
Magic-F1 does not induce myoblast proliferation
Since HGF has been shown to affect satellite cell proliferation
and differentiation, the action of the Magic-F1 on these biological
processes was investigated by different approaches. We first
subjected the myogenic cell line C2C12 [28] to different biological
and biochemical assays in the presence of recombinant Magic-F1.
Myoblast proliferation was evaluated by culturing C2C12 cells
with Magic-F1, HGF or no factor as control. While HGF induced
myoblast proliferation in a dose-dependent manner, Magic-F1 did
not affect proliferation even at high concentrations as well as NK2
(Fig. 1E). As phosphorylation of Met is necessary for the activation
of the HGF signaling cascade [1], we tested whether Magic-F1
could induce Met receptor phosphorylation. Immunoprecipitation
analysis of Met followed by Western blot analysis using anti-
phosphotyrosine antibodies revealed that both HGF and Magic-
F1 induce phosphorylation of Met in C2C12 cells (Fig. 1D),
indicating that the inability of Magic-F1 to affect myoblasts
proliferation is not due to defective receptor activation. Since HGF
is able to promote cell proliferation through the ERK pathway and
to prevent apoptosis through AKT signaling [29], we next tested
the ability of Magic-F1 to activate these two distinct pathways.
While HGF induced phosphorylation of both MAPK and AKT.
Magic-F1, differently form NK2, induced phosphorylation of
AKT. Moreover, consistent with the idea that HGF and Magic-F1
compete for the same binding site on Met, Magic-F1 inhibited
HGF-mediated MAPK phosphorylation (Fig. 1F).
Magic-F1 promotes myoblast differentiation and survival
Next, we generated several stable clones of C2C12 myoblasts
expressing Magic-F1 (Fig. 2A). Surprisingly, C2C12 cells expressing
Magic-F1 differentiated at a faster rate compared to controls. In fact,
they started to express myosin heavy chain, a marker of terminal
differentiation, only one day following switch to differentiation
medium (Fig. 2B). Consistent with accelerated differentiation, the
myogenic markers MyoD and Myf5 were up-regulated while the
Pax3 protein was down-regulated (Fig. 2D). Moreover, Magic-F1
increased the expression of 30 out of 36 genes known to be
upregulated during C2C12 differentiation [30]; Figure S2. Magic-
F1-expressing C2C12 cells fused into myotubes containing on
average more nuclei than controls, while HGF did not affect
myoblast fusion (Fig. 2C). Interestingly, in stable clones expressing
Magic-F1, myostatin expression but not follistatin or IGF1
expression was down-regulated earlier compared to controls
(Fig.2E).Thisisinagreementwithpreviousdatashowingpromotion
of myoblast differentiation and muscle hypertropy following
myostatin ablation [31,32]. Finally, cells expressing Magic-F1
displayed a marked reduction in the expression of several pro-
apoptoticgenes,includingBad,Bax andp53(Fig.2F)suggestingthat
the anti-apoptotic properties documented for HGF [29] are
conserved in Magic-F1. Thus, Magic-F1 is an engineered, HGF-
derived protein that elicits a selective pattern of biological responses
on myoblasts. Firstly, it is a partial agonist of Met that activates the
AKT pathway but not the ERK pathway. Secondly, it conserves the
anti-apoptotic activity of HGF but not its mitogenic properties.
Thirdly, it significantly enhances the differentiation potential of
myoblasts without affecting their proliferation. The latter property is
likely to be due to its inability to activate the ERK pathway.
Electro-enhanced Magic-F1 DNA transfer in vivo
promotes muscle hypertrophy and protects myocites
against apoptosis
Efficient secretion of therapeutic proteins can be induced into
skeletal muscle through electro-enhanced DNA transfer [33]. Using
Inducing Muscular Hypertrophy
PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3223Figure 1. Magic-F1 elicits partial activation of the Met pathway in C2C12 myogenic cells. (A) Schematic representation of the Magic-F1
molecule. The indicated restriction sites refers to the corresponding cDNA map. BamH1 and Sal1 were destroyed and the DNA fragment was cloned
into the EcoRV restriction site of the pIRES-neo plasmid. (B) Purification of Magic-F1 by metal-chelate affinity chromatography. Following elution,
fractions (F1-6) were resolved by SDS-PAGE in non-reducing conditions along with bovine serum albumine (BSA) standards. Proteins were revealed
by Coomassie staining. MW, molecular weight; kDa, kilo Dalton units (C) ELISA binding assay. A fixed amount (100 ng/well) of Fc-Met chimera was
absorbed in solid phase and exposed to increasing concentrations of HGF or Magic-F1 in liquid phase. Binding was revealed using biotinylated anti-
HGF antibodies. (D) Met phosphorylation analysis in C2C12 cells. Cells were stimulated with no factor (Ctrl), 5 nM Magic-F1 (M) or 5 nM HGF (HGF),
and Met phosphorylation was determined using anti-phosphotyrosine antibodies (IB). The same blots were reprobed with anti-Met antibodies to
normalize the amount of receptor immunoprecipitated (IP). (E) Growth curves of C2C12 cells treated with the indicated concentrations of Magic-F1,
HGF or no factor. (F) Signal transduction analysis. Cells were stimulated with no factor (Ctrl), 5 nM HGF, 5 nM NK2, 5 nM Magic-F1 (M), or 5 nM Magic-
F1 and 5 nM HGF (M+HGF). Cell lysates were analyzed by Western blotting using antibodies against ERK or AKT (total) as well as antibodies against
the phosphorylated forms of these signal transducers (ph).
doi:10.1371/journal.pone.0003223.g001
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muscles in vivo. A plasmid encoding Magic-F1 was co-electroporated
with a plasmid expressing b-galactosidase into the tibialis anterior and
quadriceps muscles of juvenile mice (postnatal day 10) as described.
A vector encoding HGF and an empty vector without insert
were used as controls. Histological analysis using X-gal staining
showed that b-galactosidase was widely expressed one week after
intra-muscular DNA electrotransfer but rapidly declined after-
wards (Fig. 3A). Expression of the foreign genes also reached its
maximum one week post-transfer and lasted for up to three weeks,
as determined by RT-PCR analysis (Fig. 3B). Morphometric
analysis performed on the tibialis anterior and quadriceps (9 mice for
each group and 300–460 fibres for each sample were analyzed)
revealed a significant increase of the cross-sectional area of Magic-
F1-electrotransferred muscles compared to the control muscles
starting two weeks after electrotransfer (Fig. 3C) as well as an
increase in fiber perimeter (not shown). Representative images of
electroporated quadriceps stained with hematoxylin and eosin are
shown in Fig. 3D. Next, we evaluated whether Magic-F1 could
protect muscle cells against apoptosis. To this end, we performed a
Figure 2. Morphological analysis of C2C12 cells expressing Magic-F1. (A) Magic-F1 detection in the culture media of stably transfected
clones by Western blot analysis. (B) Immunofluorescence analysis for myosin heavy chain expression on Magic-F1 expressing clones (right panels) or
control clones (left panels). Cells were analyzed after 1 day (1 d), 3 days (3 d) and 5 days (5 d). Nuclei were stained with DAPI. (C) Fusion index of
C2C12 cells stably transfected with Magic-F1, HGF or mock-transfected (Ctrl). Fusion index is the ratio between the number of myocites with two or
more nuclei versus the total number of myocites. (D) RT-PCR analysis of myogenic transcription factors (Myf-5, Pax3 and MyoD) on stably transfected
clones (M) or control cells (C). GAPDH is used as internal control. (E) RT-PCR analysis of myostatin, follistatin and IGF1 expression in proliferating (P)
versus differentiating (D) C2C12 cells. C, control cells; M, cells expressing Magic-F1. Skeletal muscle tissue (sk Mus) and a mouse embryo at 10.5 days
(E10.5) were also used as controls. GAPDH was used as an internal control. (F) RT-PCR analysis of pro-apoptotic genes Bad, Bax and p53 in C2C12
clones stably transfected with Magic-F1 (M) or control cells (Ctrl). GAPDH was used as an internal control.
doi:10.1371/journal.pone.0003223.g002
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electrotransfer. This analysis indeed showed a decreased number
of apoptotic nuclei (TUNEL positive) in muscles treated with
either Magic-F1 or HGF (Fig. 3E). Taken together, the in vitro and
in vivo data presented here suggest that Magic-F1 induces
hypertrophy in the developing skeletal muscle by enhancing the
differentiation and fusion ability of myogenic cells and by
protecting them against apoptosis.
Magic-F1 transgenic mice display hypertrophic fast-
twitch fibers and improved running ability
To further investigate the ability of Magic-F1 to promote muscle
hypertrophy, we generated transgenic mice expressing Magic-F1
under the control of the skeletal muscle-specific regulatory elements
of the rat myosin light chain MLC1F gene locus [34]; Fig. 4A.
MLC1F/Magic-F1 transgenic lines were identified by genotyping
PCR with primers specific for the Magic-F1 coding sequence
Figure 3. In vivo electrotransfer-mediated delivery of Magic-F1 to muscles. 10-day-old mice were subjected to in vivo electroporation of a
combination of two plasmids expressing beta-galactosidase (b-gal) and HGF or Magic-F1, respectively. (A) Percent of b-gal-positive fibers following X-
gal staining 4 weeks after electroporation. Representative images of electroporated muscles 1 week (1 w) and 4 weeks (4 w) after electrotransfer are
shown in the upper panel. (B) RT-PCR analysis of electroporated muscles expressing HGF or Magic-F1 (data refers to samples obtained from
quadriceps). (C) Histograms of morphometric analysis performed on tibialis anterior. Nine mice per group were analyzed. For each mouse, 300–460
fibers were examined (p,0.01). (D) H&E staining of quadriceps electroporated muscles. Note the larger fibers formed after 4 weeks in the Magic-F1
group relative to the control (Ctrl) or HGF group. (E) Tunel analysis of quadriceps 1 week after in vivo electrotransfer.
doi:10.1371/journal.pone.0003223.g003
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detected by RT-PCR in all muscles analyzed; on the contrary, no
signal was detected in the liver of transgenic mice or in any organ of
wild-type animals (Fig. 4C). Protein expression in fast transgenic
muscles was also confirmed by Western blotting analysis (Fig. 4D).
Embryonic and post-natal development of MLC1F/Magic-F1
transgenic animals occurred without overt differences compared to
control mice. Skeletal muscle hypertrophy became apparent at
around 5 weeks of age, consistent with the in vivo electrotransfer
results. Morphometric analysis of the fast tibialis anterior muscles in
transgenicmiceshowedastatisticalsignificantincrementofmyofiber
cross-sectional areas compared to age-matched wild-type controls
(Fig. 4E, left histogram). Interestingly, morphometric analysis of
slow-twitch soleus muscles unveiled no difference between transgenic
and control animals (Fig. 4E, right histogram), even though
transgene expression was detected in the soleus muscle (see Fig. 4C).
A treadmill test was performed in order to evaluate the effect of
Magic-F1 on muscular performance. This in vivo motility assay
revealed that MLC1F/Magic-F1 transgenicmicecover on average a
longer distance in comparison to their wild-type counterparts
(Fig. 4F), thus demonstrating that Magic-F1-induced muscle
hypertrophy results in increased muscular performance.
Figure 4. Morphological and functional analysis of Magic-F1 transgenic mice. (A) Transgenic construct used for two different
microinjections into ES cells. (B) Representative example of tail genotyping by PCR. The M13newborn is positive for Magic-F1 integration. In two
different microinjections we obtained 2 founders out of 14, that generated two different transgenic colonies. (C) RT-PCR analysis of Magic-F1
expression in transgenic (MLC1F/Magic-F1) and wild-type muscles (WT). No signal was detected in the liver of transgenic mice (Liv) or in any organ of
wild-type animals. (D) Western blot analysis of Magic-F1 expression using anti-HGF antibodies or anti-GAPDH antibodies as control. A 60 kDa band
appeared only in muscles from transgenic mice. (E) Morphometric analysis of tibialis anterior (left histogram) and soleus (right histogram) muscles. For
each sample; 300–400 fibers were analyzed. (F) Distance performed by transgenic and control mice on a treadmill test. For more information, please
refer to the Materials and Methods section.
doi:10.1371/journal.pone.0003223.g004
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PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3223Magic-F1 transgenic mice display enhanced muscle
regenerative capacity
In muscular dystrophy disorders, fiber degeneration is only
partially counterbalanced by regeneration of new fibers by satellite
cells [35]. Hypertrophic factors represent a potential therapeutic
approach against muscle wasting. We therefore analyzed the effect
of Magic-F1 on muscle regeneration. Muscle damage was induced
in the tibialis anterior muscles of adult MLC1F/Magic-F1 transgenic
or wild-type mice by a single intramuscular injection of
cardiotoxin. MLC1F/Magic-F1 transgenic animals responded to
muscle crush by rapidly activating the regenerative program.
Three days after cardiotoxin injection, an enhanced number of
centrally-nucleated regenerating myofibers and an increased
expression of the regeneration hallmark protein, embryonic
myosin heavy chain (MyHC), was observed in damaged muscles
of transgenic mice compared to those of age-matched wild-type
animals (Fig. 5A). Furthermore, one week post-injury, muscle
fibers of MLC1F/Magic-F1 transgenic mice were characterized by
enhanced peripherycal localization of nuclei and by the down-
regulation of embryonic MyHC, indicating successful completion
of the regeneration program. In contrast, in wild-type animals,
regeneration persisted for a few more days (Fig. 5A). Interestingly,
also regenerating centrally-nucleated fibers in the MLC1F/Magic-
F1 transgenic mice appeared to have a greater cross-sectional area
in comparison to wild-type animals after 3 days of injury (Figure
S3). Consistent with these observations, satellite cells collected
from MLC1F/Magic-F1 transgenic showed enhanced differenti-
ation potential in vitro compared to satellite cells from wild-type
mice. Furthermore, satellite cells from MLC1F/Magic-F1 trans-
genic mice were more differentiation-prone as revealed by smaller
clone size and accelerated appearance of differentiated myotubes
(Fig. 5B). Moreover, cardiotoxin induced a rapid apoptotic
response in injected areas, which appeared to be strongly reduced
in MLC1F/Magic-F1 transgenic animals (Fig. 5C and D). Rapid
and efficient muscle regeneration in transgenic muscles subjected
to cardiotoxin treatment is also explained by earlier and increased
expression of the muscle master genes MyoD and Myf5 (Fig. 5E).
This resulted in reduction of central nucleated fibers at 10 days
following cardiotoxin treatment (Fig. 5F) and in greater cross-
sectional area of regenerated transgenic fibers compared to wild-
type animals (Figure S3B).
Magic-F1 partially rescues the dystrophic phenotype of
alpha-sarcoglycan knock-out mice
The therapeutic potential of Magic-F1 was tested in alpha-
sarcoglycan (a-SG) knock-out mice, which represent an established
animal model of muscular dystrophy. Due to their genetic defect,
these mice display persistent degeneration and regeneration areas in
skeletal muscles [36]. To achieve Magic-F1 expression in these mice,
weundertooktwo differentapproaches.Firstly,wecrossedMagic-F1
transgenic mice with a-SG knock-out animals, thus generating a-SG
knock-out mice expressing Magic-F1 in their muscles (Fig. 6A).
Secondly, we engineered an adenoviral vector [37] expressing
Magic-F1 and administered it by intramuscular injection to 45 day-
old a-SG knock-out female mice under immunosuppressive
conditions [38]. Morphological analysis of the tibialis anterior of a-
SG knock-out/Magic-F1 transgenic mice revealed significant
muscular hypertrophy compared to a-SG knock-out controls, which
persisted until at least 6 months of age (Fig. 6B). Consisted with this,
a-SG knock-out/Magic-F1 transgenic mice performed much better
thancontrola-SG knock-out miceina classictreadmilltest(Fig. 6C).
Adenovirus-mediated delivery of Magic-F1 also ameliorated the
dystrophic phenotype of a-SG knock-out mice, although to a
reduced extent compared to a-SG knock-out/Magic-F1 transgenic
mice (Fig. 6C). This may be due to the lower expression levels of
Magic-F1 achieved by adenoviral transduction (see Western blot
analysis inFig. 6A). In any case, the values obtained were statistically
significant compared to dystrophic animals treated with a control
adenovirus (Fig. 6C).
Discussion
Protein engineering allows creating recombinant factors dis-
playing selective biological functions. This is particularly useful for
pleiotropic factors eliciting several different biological responses
like HGF. Magic-F1, an engineered protein derived from HGF,
maintains the ability to protect cells against apoptosis and to
promote myoblast differentiation, but is devoid of any mitogenic
activity typical of its parental factor. This results in remarkable
enhancement of skeletal muscle regeneration without induction of
cell proliferation, a crucial feature for its potential therapeutic
application. Notably, muscle hypertrophy was induced in normal
and regenerating muscle both when Magic-F1 was present as a
transgene and when it was delivered to post-natal muscles, as it
would occur in a cell or gene therapy context.
The potential relevance of inducing muscle hypertrophy to the
treatment of muscle disorders in humans has been suggested by
studies involving mdx mice, which carry a mutation in the
dystrophin gene and therefore serve as a genetic model of
Duchenne’s muscular dystrophy [39]. For example, mdx mice
lacking myostatin were found not only to be stronger and more
muscular than their mdx counterparts with normal myostatin, but
alsoto havereduced fibrosis and fat deposition, suggesting sustained
muscle regeneration [40]. Furthermore, injection of neutralizing
monoclonal antibodies directed against myostatin into either wild-
type or mdx mice increases muscle mass and specific force,
suggesting that myostatin plays an important role in regulating
muscle growth in adult animals [41]. Magic-F1 is a molecule with a
potential clinical applicationas it can induce muscle hypertrophy by
both down-regulating myostatin and directly activating MyoD,
Myf5 and several anti-apoptotic pathways. Interestingly, no side
effects have been observed in skeletal muscles following electro-
enhanced Magic-F1 DNA transfer or in transgenic mice expressing
the Magic-F1 under the control of a muscle-specific promoter.
Our data showing the inability of Magic-F1 to induce the ERK
pathway together with an inhibitory interference with HGF-
induced ERK activation are particular relevant to a potential
therapeutic use of this engineered factor. In fact, several tissues
other than myocytes and satellite cells express the Met receptor,
including epithelial cells of kidney, liver, lung, skin, breast and the
whole gastrointestinal tract, as well as neurons, endothelial cells
and hematopoietic precursors [1,5]. Furthermore, Met overex-
pression is a very frequent event in human cancer [42]. This raises
the concern that stimulating the proliferation of Met-expressing
cells may lead to tumor formation or progression [43]. In this
regard, the lack of any mitogenic activity makes Magic-F1 a
potentially safe cytokine for cell therapy.
Because of its potent and selective effect on myoblast survival
and differentiation, Magic-F1 promoted muscular hypertrophy in
all mouse models analyzed. This biological activity, revealed by in
vitro experiments, was extensively confirmed by the analysis of
muscles treated by electro-enhanced DNA transfer or derived
from transgenic mice expressing Magic-F1 under the control of a
muscle-specific promoter. Interestingly, a statistically significant
increase of myofiber cross-sectional areas was observed in the
tibialis anterior muscles but not in slow-twitch soleus muscles. This
can be attributed to the specificity of the promoter, active in fast
Inducing Muscular Hypertrophy
PLoS ONE | www.plosone.org 7 September 2008 | Volume 3 | Issue 9 | e3223Figure 5. Magic-F1 promotes muscular regeneration. (A) Immunofluorescence analysis of muscle fibers using antibodies against embryonic
myosin heavy chain (red) or laminin (green) in the tibialis anterior of transgenic and wild-type mice. Nuclei were stained with DAPI. (B)
Immunofluorescence analysis for desmin (middle panels, in green) and myosin heavy chain (lower panels, in red) of satellite cells isolated from tibialis
Inducing Muscular Hypertrophy
PLoS ONE | www.plosone.org 8 September 2008 | Volume 3 | Issue 9 | e3223Figure 6. Magic-F1 increases muscle strength in a-SG knock-out mice. (A) After performance of an exhaustion treadmill tests, mice were
sacrificed and Magic-F1 expression was evaluated by RT-PCR (left panel, upper lanes) and Western blot analysis (right panel, upper lanes) on tibialis
anterior muscles of the indicated mice. Lane 1, a-SG knock-out dystrophic mice injected with an adenovirus expressing Magic-F1; lane 2, Magic-F1
transgenic mice; lane 3, a-SG knock-out/Magic-F1 transgenic mice; lane 4, a-SG knock-out dystrophic mice injected with an empty adenovirus.
GAPDH was used as internal control (bottom panel). (B) H&E staining of tibialis anterior (left upper panel) and quadriceps (left lower panel) muscles
from 3 month-old Magic-F1 mice, tibialis anterior of double transgenic a-SG knoc-out/Magic-F1 transgenic mice (upper middle panel), a-SG knock-out
mice (right upper panel), a-SG knock-out mice injected with Ad-Magic-F1 (middle lower panel) or with Ad-Mock (right lower panel). Mice were
sacrificed 14 days after the exhaustion treadmill tests. The bar is a 50 mm marker. (C) Exhaustion treadmill tests carried on wild-type mice (blue label),
a-SG knock-out/Magic-F1 transgenic mice (red label), a-SG knock-out mice injected with Ad-Magic-F1 (red-black label) or Ad-Mock (black label). Note
that mice expressing Magic-F1 showed increased running performance compared to Ad-Mock-injected mice. Muscle strength of treated and control
animals was measured as time (left histogram) or distance to exhaustion (right histogram; n=4, p,0.05).
doi:10.1371/journal.pone.0003223.g006
anterior of Magic-F1 transgenic mice (M) and wild-type (WT) mice subjected to cardiotoxin treatment. Nuclei are stained with DAPI (in blue). The upper
panels show a phase contrast image of satellite cell clones, 3 days after low density seeding. (C) TUNEL analysis of tibialis anterior after 3, 7 and 14 days
after cardiotoxin treatment.(D) Quantificationofapoptotic nuclei (ap nuclei) relative tothe experiment describedinC.Redline,transgenic mice;blueline,
wild-typemice.(E)RT-PCRanalysisofmyogenictranscriptionfactorexpression(MyoDandMyf5)conductedontibialisanteriorfromtransgenic(M)orwild-
type (WT) mice. (F) Representative images of tibialis anterior muscles stained with H&E extracted from Magic-F1 transgenic mice and wild-type mice 10
days after cardiotoxin treatment. Note the larger size of fibers in the Magic-F1 group (M) compared to the control group (WT).
doi:10.1371/journal.pone.0003223.g005
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F1 (escaping from fast-twitch muscles) is not enough to induce
muscle hypertrophy. Moreover, following cardiotoxin treatment,
regenerating centrally-nucleated fibers in the MLC1F/Magic-F1
transgenic mice appeared to have a greater cross-sectional area
compared to wild-type animals. This can be explained by the
enhanced differentiation potential of satellite cells, which indeed
displayed an earlier differentiation program in vitro compared to
cells isolated from wild-type mice. We previously reported the
presence of myogenic precursors, named mesoangioblasts, in the
skeletal muscles of mice [44], dogs [45] and humans [46]. These
cells could also be positively affected by Magic-F1 and we cannot
exclude their participation in the regeneration of skeletal muscle
tissues. On the other hand, the rapid apoptotic response in
cardiotoxin-treated muscles is strongly reduced in MLC1F/Magic-
F1 transgenic mice. This results in a more evident muscular
hypertrophy of transgenic muscles.
Several authors have reported that HGF inhibits muscle
differentiation both in vitro and in vivo [19,20]. Recently, it has
been reported that HGF gene therapy improves LV remodeling
and dysfunction post-infarction through promotion of cardiomy-
ocyte hypertrophy, and that HGF plays a role in the induction of
stem cell commitment to the cardiomyocyte lineage [47–49].
Magic-F1 exhibits biological effects in the renewal of skeletal
muscles tissues similar though not identical to those observed for
HGF in cardiac tissue regeneration. Further studies are necessary
to elucidate the different potential effects of HGF in this context
and –in this sense– supplementary studies on Magic-F1 signal
transduction could provide useful information.
Successful adenovirus-mediated gene delivery under immuno-
suppressive conditions in adult muscles was previously demon-
strated [50,51]. In the present study, we transduced muscle fibers
of juvenile a-SG knock-out mice with adenoviral vectors carrying
Magic-F1 cDNA. All injected mice showed a physiological benefit
and performed much better compared to mock-treated dystrophic
animals in treadmill tests. As discussed, the less efficient rescue of
the dystrophic phenotype by adenovirus-mediated Magic-F1
delivery compared to the crossing with Magic-F1 transgenic mice
is conceivably due to incomplete muscle transduction. Important-
ly, in those mice in which all dystrophic fibers were transduced, the
treadmill test performance was similar to that covered by control,
non-dystrophic animals (not shown).
In conclusion, Magic-F1 is a soluble, engineered factor that
displays marked anti-apoptotic and pro-differentiative clues on
muscle precursors. Its ability to promote and enhance muscle
regeneration makes it a potential candidate molecule for
regenerative medicine, particularly for muscular dystrophy
syndromes and other muscle degenerative disorders. Given the
small size of its cDNA (approximately 1 kb), Magic-F1 may be
used alone in a gene therapy setting or inserted as a second
adjuvant gene in a vector already encoding a therapeutic gene, for
example encoding a deacetylase inhibitor [52]. The lack of
mitogenic activity allows a safe use of Magic-F1 as a therapeutic
cytokine, promoting muscle regeneration without the potential risk
of stimulating uncontrolled proliferation.
Materials and Methods
Magic-F1 Factor engineering and purification
Magic-F1 is an engineered factor containing two HGF NK2
domains joint by a linker. The exact amino acidic sequence of
Magic-F1 corresponds to: residues 1–285 of human HGF (Gene
Bank # M73239); a linker with the sequence (GGGGS)3;r e s i d u e s
30–285 of human HGF; a poly-histidine tag with the sequence
DDDKHHHHHH. Factors were produced in a CHO cell line
(ATTC, Rockville, Maryland). Purification was performed by dual-
step affinitychromatography using a heparin-Sepharose columnand
aN i
2+-chelate column (Amersham Pharmacia, Uppsala, Sweden).
Activated human recombinant HGF was purchased from R&D
Systems (Minneapolis, Minnesota) while Metron Factor-1 (Metr. in
Figure S1) recombinant protein [53] was produced at Dompe ´
Pharmaceutical Company S.p.A. (L’Aquila, Italy).
ELISA binding assay
HGF and FcMET (a chimera consisting of the extracellular
domain of MET fused to the Fc region of a human IgG1) were
purchased from R&D Systems. Binding of Magic-F1 and HGF to
Fc-Met was measured by ELISA using the receptor in solid phase
and the ligands in liquid phase. A fixed concentration (100 ng/
well) of Fc-Met was adsorbed to 96-well ELISA plates and
incubated with increasing concentrations of ligands. Binding was
revealed using biotinylated anti-HGF antibodies (R&D). Binding
data were analyzed and fit using Prism software (Graph Pad
Software, San Diego, California).
Immunoreagents
The antibodies used in this study were obtained as follows: anti-
human HGF for both Western blotting and immunoprecipitation,
Santa Cruz Biotechnology (Santa Cruz, California); anti-human
Met for Western blotting, Santa Cruz; anti-human Met for
immunoprecipitation, as described [5]; anti-mouse Met, Santa
Cruz; anti-AKT and anti-phospho-AKT, New England Biolabs
(Beverly, Massachusetts); anti-MAPK (p42–44/ERK) and anti-
phospho-MAPK, Promega (Madison, Winsconsin); anti-laminin
polyclonal rabbit antibodies, Sigma (St. Louis, Missouri); anti-
desmin rabbit polyclonal antibody, Sigma; MF20 and embryonic
myosin monoclonal antibody, Developmental Studies Hybridoma
Bank (Iowa City, Iowa).
Receptor activation and signal transduction
For receptor activation analysis, quiescent cells plated on
collagen-coated 100 mm plates (Becton Dickinson, Franklin
Lakes, New Jersey) were stimulated with 5 nM HGF or Magic-
F1 for 30 min at 37uC and then lysed as described [54]. Lysates
were immunoprecipitated with anti-Met and analyzed by Western
blotting using anti-phosphotyrosine antibodies. For signal-trans-
duction analysis, cells were stimulated as above for different times
and then lysed. For MAPK and AKT activation, lysates were
directly analyzed by Western blotting using antibodies specific for
the activated forms of the signaling molecules. Quantification of
enhanced chemiluminescence signal was performed using a
STORM apparatus and Image Quant software (Molecular
Dynamics, Amersham Biosciences, Sunnyvale, California).
Cell cultures and bioassays
Mouse myogenic cell line C2C12 was maintained in DMEM
supplemented with 2 mM glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin and 10% FBS. C2C12 cells were induced
to differentiate into myotubes by replacing 10% FBS with 2%
horse serum (HS). Differentiation was completed in 7–8 days. All
cultures were performed at 37uC in a humidified incubator with
5% CO2 and 95% air. Satellite cells were prepared as previously
described [46]. Briefly, muscle fragments were digested with 2%
collagenase II (Invitrogen, Carlsbad, California) for 60 min at
37uC. Digested cells were discarded and fragments were incubated
again with 0.05% trypsin (Invitrogen) for 15 min at 37uC with
gentle agitation. After the incubation, isolated cells were collected
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digested (usually three times). Isolated cells were pooled,
centrifuged and resuspended in DMEM supplements with 20%
pre-screened FCS, 1% gentamycin, and plated onto collagen
coated dishes at a density of 10
4 cells6cm
2. Contamination by
non-myogenic cell was reduced by pre-plating the cell suspension
onto plastic dishes where fibroblasts tend to adhere more rapidly.
Differentiation was induced shifting the medium to DMEM
supplemented with 2% horse serum. Cell morphology was
examined daily with a phase-contrast microscope connected to
an image analyzer. Cells were trypsinized daily and counted on a
hemocytometer. Cell viability was determined by trypan blue dye
exclusion assay. Cell cytotoxicity was performed using an XTT-
based in vitro toxicology assay kit (Sigma) according to manufac-
turer’s protocol. Incubation medium was collected after 3 hours
and read spectrophotometrically at a wavelength of 450 nm.
Background signals, obtained from plates without cells, were
subtracted from sample readings. Apoptosis was quantified using
an ApopTag Fluorescein In situ Apoptosis detection kit (Chemi-
con, Temecula, California) according to the manufacturer’s
protocol. Cell differentiation was carried out for 8 days. Cells
were grown on 6 cm Petri dishes until sub-confluent, washed with
PBS, fixed with 4% paraformaldehyde at room temperature for
10 minutes and then permeabilized with 0.1% Triton X-100 in
PBS for 5 minutes. After incubation with PBS containing 10%
normal serum, samples were incubated overnight at 4uC with anti-
GFP at 1:200 dilution, anti myosin heavy chain (MF20) antibody
at 1:2 dilution. After incubation, cells were washed three times in
PBS and incubated with the appropriate FITC- or TRITC-
conjugated secondary antibodies for 1 hour at room temperature.
After washing in PBS, cells were analyzed under a fluorescent
microscope and photographed. As a control for the immunoflu-
orescence method, we omitted the primary antibody and no
staining was detected under these conditions. Cell nuclei were
counterstained with DAPI.
Plasmids and DNA preparation
Magic-F1 was cloned into pIRESneo (Clontech, Italy) for
C2C12 transfection experiments whereas it was cloned into
pcDNA3 (Invitrogen) containing the cytomegalovirus (CMV)
promoter for electrotransfer experiments (pCMV-Magic-F1); a
pCMV-bgal plasmid coding for beta-galactosidase and a pCMV-
hHGF plasmid coding for human hepatocyte growth factor were
also used. Plasmids were prepared by using standard procedures.
All plasmid preparations was obtained using a GenElute
TM HP
Endotoxin-Free Plasmid Maxiprep Kit (Sigma) and contained a
high percentage of supercoiled DNA (70–80%). No RNA was
detectable by gel electrophoresis.
DNA electro-transfer and animal handling
Mouse experiments were performed in the San Raffaele
Hospital SPF Animal Care Facilities according to international
ethical guidelines (EEC Council Directive 86/609; NIH Guide for
the Care and Use of Laboratory Animals, 1985). Authorization for
animal experimentation was obtained from the Italian Ministry of
Health. Gene transfer into skeletal muscle mediated by electric
pulse was performed as previously reported [33]. Briefly, 20 mgo f
DNA in 10 ml of PBS was injected into the tibialis anterior or in the
quadriceps muscle of anesthetized, 10 day-old C57Bl/6 mice (Iffa
Credo, St. Germain sur l’Arbresle, France) with a Hamilton
syringe. There were 10 muscles included in each experimental
group. Five minutes after DNA injection trans-cutaneous electric
pulses were applied by two stainless steel plate electrodes placed
3.8–4.3 mm apart, at each side of the leg. Electrical contact with
the leg skin was ensured by shaving each leg and applying a
conductive gel. Square-wave electric pulses (eight pulses; 200 V/
cm; 20 ms per pulse; 1 Hz) were generated by a digital Stimulator
(Panlab 3100, Biological Instruments, Varese, Italy).
Muscular regeneration analysis
Acute skeletal muscle damage was induced in male and female
MLC1F/Magic-F1transgenic mice and control mice (7 animals/
group) by i.m. injection of 10 nM cardiotoxin (Gentaur, Brussels,
Belgium) in physiologic solution (0.9% w/v NaCl). Control mice
were injected with physiologic solution alone. At 3, 7, and 14 days
after drug injection, mice were sacrified and subjected to
histological evaluation and morphometric analysis of tibialis anterior.
After excision, muscles were sectioned (4–6 mm) and processed for
immunofluorescence analysis using the primary antibodies listed
above. All sections were washed three times in PBS and incubated
with 10% donkey serum for 30 min at RT before the addition of
the appropriate Alexa 488-, Alexa 594- or Alexa 647-conjugated
donkey secondary antibodies. Alternatively, some sections were
stained with hematoxylin and eosin and examined by an
independent histopathologist not informed of sample identity to
determine muscle fiber sizes using Scion Image software (Scion,
Frederick, Maryland).
Biochemical and molecular analysis
Western blot analysis of cells or tissues was performed as
described [41], 55. Total RNA from control or treated cells was
extracted using Trizol reagent (Invitrogen) and analysed by PCR
after reverse transcription with random hexamers. RT-PCR
analysis has been performed using the following primers:
Bax
Fw 59-TGTTTGCTGATGGCAACTTC-39
Rv 59-GATCAGCTCGGGCACTTTAG-39
Bcl-2
Fw 59-GGGATGCCTTTGTGGAACTA-39
Rv 59-CTCACTTGTGGCCCAGGTAT-39
P53
Fw 59-GGATGCCCGTGCTGCCGAGGAG-39
Rv 59-AGTGAAGGGAC TAGCATTGTC-39
Magic-F1
Fw 59-TTCAGAAGTTGAATGCATGACCTG-39
Rv 59-TCTTCTTTTCCTTTGTCCCTCTAG-39
GAPDH
Fw 59-TTCACCACCATGGAGAAGGC-39
Rv 59-GGCATGGACTGTGGTCATGA-39
MyoD
Fw 59-TGCACTTCCACCAACCCCAACCAGC-39
Rv 59-CCTGGACTCGCGCACCGCCTCACT-39
Met
Fw 59-AGAAATTCATCAGGCTGTGAAGCGCG-39
Rv 59-TTCCTCCGATCGCACACATTTGTCG-39
PAX3
Fw 59-AGGAGGCGGATCTAGAAAGGAAG-39
Rv 59-TGTGGAATAGACGTGGGCTGGTA-39
Myf5
Fw 59-GAGCTGCTGAGGGAACAGGTGGAGA-39
Rv 59-GTTCTTTCGGGACCAGACAGGGCTG-39
IGF1
Inducing Muscular Hypertrophy
PLoS ONE | www.plosone.org 11 September 2008 | Volume 3 | Issue 9 | e3223Fw 59-CTGTGCCCCACTGAAGCCTA-39
Rv 59-GGACTTCTGAGTCTTGGGCATG-39
Myostatin
Fw 59-AGTGACGGCTCTTTGGAAGATG-39
Rv 59-AGTCAGACTCGGTAGGCATGGT-39
Follistatin
Fw 59-CTGTACAAGACCGAACTGAGC-39
Rv 59-TCCACAGTCCACGTTCTCACA-39
Generation of Magic-F1 and a-SG knock-out/Magic-F1
transgenic mice
We constructed the transgene by inserting the Magic-F1
construct into the pMex plasmid containing the 1,500-bp fragment
of the MLC promoter, an 840-bp fragment of SV40 poly(A), and a
900-bp fragment from the 39 end of the MLC1f/3f gene, which
acts as an enhancer [34]; provided by Dr. Antonio Musaro `,
University of Rome, Italy. We microinjected the transgene into the
male pronucleus of fertilized eggs from FVB mice (Jackson
Laboratories, Bar Harbor, Maine) that were implanted into
pseudopregnant foster mothers. We identified positive transgenic
mice by PCR. For PCR detection, sense and antisense primers
specific respectively for the MLC1F promoter and the linker
region of Magic-F1 were used. Transgenic founders were mated
with wild-type FVB mice to generate F1 offspring. After obtaining
MLC1F/Magic-F1 mice we mated them with a-SG knock-outs
[36] to generate a-SG knock-out/Magic-F1 transgenic mice. The
animals were housed in a temperature controlled (22uC) room
with a 12:12 hours light-dark cycle. All studies have been
performed using Tg:MLC1F/Magic-F1 hemizygous mice, follow-
ing the protocols approved by the Animal Care and Use
Committee of the San Raffaele Institute (IACUC 264) and
communicated to the Ministry of the Health and local authorities
according to Italian law.
Adenovirus preparation and administration
pAd/CMV-Magic-F1/V5-DEST was engineered using the
ViraPower Adenoviral Expression System from Invitrogen. The
Adenoviral vector was linearized with PacI restriction enzyme and
transfected into 293A cells. Cells were grown in Iscove Medium
supplemented with 10% heat-inactivated FBS, 2 mM l-glutamine,
50 units/ml penicillin, 50 mg/ml streptomycin (Sigma). After
complete detachment of cells, the supernatant was used to
superinfect 293A cells. The purification of Adenoviral particles
was performed with Vivapure AdenoPACK 100TM (Sartorius,
Goettingen, Germany) starting from 200 ml of cell culture.
Juvenile a-SG knock-out mice (8 weeks old) were anesthetized
with an intraperitoneal injection of avertin (0.2 ml/10 g body-
weight of a 1.2% solution), hair was shaved from the skin and pAd-
Magic-F1 suspension (2.5610
9 pfu diluited in 30 ml of PBS
containing 100 ng of VEGF) were injected i.m. with a 30-gauge
needle in the center of gastrocnemius, quadriceps and tibialis anterior.T o
prevent an immune-mediated clearance of adeno-infected fibers,
all mice were immunosuppressed with FK506 (5 mg/day/Kg,
subcutaneously). The immunosuppressive treatment was started
on the day before the Adenoviral injection and continued until
mice were sacrificed.
Treadmill analyses
Treadmill analyses were carried out using a six-lane motorized
treadmill (Exer 3/6 Treadmill; Columbus Instruments, Columbus,
Ohio) supplied with shocker plates. The first trial was performed at
low intensity and for short duration to accustom the mice to the
exercise (5 m/min for 5 minutes, after which the speed was
increased 1 m/min every 2 minutes until it reached 9 m/min).
After the first trial, the treadmill was run at an inclination of 0u at
5 m/min for 5 minutes, after which the speed was increased 1 m/
minevery1 minute.Thetestwasstoppedwhenthemouseremained
on the shocker plate for more than 20 s without attempting to re-
engage the treadmill, and the time to exhaustion was determined.
Supporting Information
Figure S1 Production of Magic-F1 in eucaryotic systems. (A) After
transient transfection with pIRES-neo-Magic-F1 plasmid, cells were
washed and incubated with fresh serum-free medium; aliquots of
medium after 3, 6 and 18 hours (lane 1, 2 and 3, respectively) were
concentrated 100 times and subjected to Western blot analysis using
anti-HGF antibodies. Cell lysate (lane 5) and mock conditioned
medium(lane 4) werealsoanalyzed. (B) Growth curvesofCHO cells
expressing Magic-F1 (#PM21) or transfected with an empty vector
(CHO). (C) Western blot analysis of conditioned media from
different CHO clones expressing Magic-F1 at different levels. (D)
Quantification of Magic-F1 protein in the conditioned medium of
clone # 21; a related recombinant protein, Metron Factor-1, was
used as standard (Metr). (E) Immunoprecipitation of Magic-F1
protein from the conditioned medium of clone # 5, 7, 21 and 25. In
somecase(# 7f),followingstorage at220uC,Magic-F1could notbe
immunoprecipitated any more. In each lane we loaded 10 mlo f
medium concentrated 100 times.
Found at: doi:10.1371/journal.pone.0003223.s001 (0.73 MB TIF)
Figure S2 Quantitative RT-PCR analysis of Magic-F1-trans-
fected C2C12 cells. The expression of 36 genes involved in
myogenic differentiation was evaluated one day after transfection
of C2C12 using quantitative real time PCR analysis. The results
indicate that 30 out of the 36 analyzed genes were upregulated in
C2C12 expressing Magic-F1 compared to controls, confirming an
enhanced rate of differentiation induced by Magic-F1 expression.
Found at: doi:10.1371/journal.pone.0003223.s002 (0.54 MB TIF)
Figure S3 Magic-F1 enhances muscle regeneration. (A) Mor-
phometric analysis on a tibialis anterior section shows a marked
increase of the fiber area in Magic-F1 transgenic mice (red bar)
relative to wild-type mice (blue bar). Note that the number of
fibers with a larger cross sectional area is higher in Magic-F1
transgenic mice when compared to wild-type mice. This effect is
evident in both regenerated and regenerating fibers (centrally
nucleated) as showed in (B), where statistical analysis is reported.
Found at: doi:10.1371/journal.pone.0003223.s003 (1.11 MB TIF)
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